Latest Research Development News

Viridis Mining and Minerals Limited (ASX:VMM) has used its FY2026 annual report to present Colossus as a rare earths project moving from study work into execution. The company has reported strong DFS economics and fresh equity funding, but still needs key permits, binding offtake and senior debt before construction can fully proceed.

Innovaero Technologies is seeking A$40 million through a proposed ASX listing to advance its OWL loitering munition program and expand manufacturing capacity. The replacement prospectus also makes clear that the company remains loss-making and heavily dependent on the Department of Defence converting development work into production orders.

Viridis Mining and Minerals has secured approval for a R$77.5 million BNDES financing facility, reducing the estimated senior debt still required for its Colossus rare earth project to about US$280 million. The 16-year facility carries an indicative current cost of approximately 4.8% and supports the project’s Brazilian processing and research infrastructure.

TALi Digital (ASX:TD1) is raising up to $3.3 million through a Security Purchase Plan and Placement to fund its acquisition of Datasphere Analytics and advance its AI-driven education platform.

CleanSpace Holdings is set to repurchase up to 10% of its shares over the next year, signalling confidence in its growth prospects and capital position.

TALi Digital is acquiring Datasphere Analytics to access cutting-edge memristive in-memory computing technology, aiming to enhance its AI-driven education platform. The company is concurrently raising $3.3 million to fund this strategic move and ongoing operations.

AoFrio’s revenue fell 21.5% in 1H26, dragged down by a 50.5% plunge in motor sales due to US tariffs, while IoT revenue grew modestly. The company launched new cellular and software platforms, raised NZD 8.9 million, and is expanding into Food Retail, but full-year revenue growth now looks unlikely.

Eagle Mountain Mining and Nittetsu Mining have signed a non-binding MOU to jointly explore new mineral project opportunities in Australia and North America, building on their existing Oracle Ridge joint venture.

Nexalis Therapeutics has ended funding negotiations with Point8 Capital after failing to secure a formal agreement, while successfully completing its IRX-616a Phase 1 trial with no serious adverse events. The company is reassessing clinical priorities amid funding uncertainty.

BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Island Pharmaceuticals has appointed Mark Herzog as Senior Global Health Security Advisor and secured roles in key Medical Countermeasures Coalition groups, boosting its US biodefence engagement ahead of pivotal Galidesivir Animal Rule studies.